Welcome to our dedicated page for Doximity SEC filings (Ticker: DOCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Doximity filings document financial results, material events, governance actions, and capital-structure details for the operator of a digital platform for U.S. medical professionals. Recent Form 8-K disclosures cover quarterly results and related exhibits, finance and legal leadership changes, Regulation FD updates, and annual-meeting voting outcomes.
The company's regulatory record also includes shareholder voting matters tied to its Class A and Class B common stock structure, director elections, auditor ratification, material agreements, and other security-holder matters. These filings describe how Doximity reports operating performance, governance changes, voting mechanics, and formal public-company events.
Doximity, Inc. reported that it has entered into an Agreement of Settlement to resolve a securities litigation case pending in the U.S. District Court for the Northern District of California. The proposed settlement calls for an aggregate payment of $31 million, which will be fully funded by insurance proceeds rather than by the company directly. If approved by the court and all conditions are met, all claims against Doximity and the named directors and officers will be dismissed without any admission of liability, fault or wrongdoing. The settlement is still subject to stockholder notice, court approval, and other customary conditions, and the company notes that appeals, opt-outs by individual plaintiffs, or issues with insurance carriers could affect the final outcome.
Doximity, Inc. director Form 4 shows an option exercise, share conversion and a small stock sale. On 12/01/2025, the reporting director exercised a stock option to acquire 2,000 shares of Class B Common Stock at an exercise price of $1.54 per share, which then converted into 2,000 shares of Class A Common Stock. The director sold 2,000 Class A shares at a price of $50.71 per share under a pre-set Rule 10b5-1 trading plan adopted on November 12, 2024. After these transactions, the director directly owned 19,839 shares of Class A Common Stock and held derivative securities representing 462,700 shares of Class B Common Stock, which are convertible into Class A shares under specified conditions.
Doximity insider files notice to sell common stock under Rule 144. The filing reports a planned sale of 2,000 shares of Doximity common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $101,420.00. These 2,000 shares were acquired on 12/01/2025 via a stock option exercise paid in cash on the same date. Common shares outstanding are listed as 137,373,858.
The filer also discloses prior sales over the past three months: 2,000 common shares on 11/03/2025 for gross proceeds of $132,880.00, 2,000 shares on 10/01/2025 for $140,020.00, and 2,000 shares on 09/02/2025 for $133,140.00. The signer represents that they are not aware of undisclosed material adverse information about Doximity.
Doximity, Inc. (DOCS) reported an insider transaction by a director on 11/21/2025. The director converted 10,000 shares of Class B Common Stock into Class A Common Stock and then sold 10,000 shares of Class A Common Stock at $50 per share.
The filing notes that the sale occurred automatically under a Rule 10b5-1 trading plan adopted on February 13, 2025. After these transactions, the director directly owned 3,221 shares of Class A Common Stock and held 333,500 derivative securities, including stock options originally granted on September 2, 2020.
A shareholder of DOCS has filed a Form 144 notice to sell up to 10,000 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE. The planned sale has an aggregate market value of $500,000, and the filing notes that 137,373,858 shares of common stock are outstanding.
The 10,000 shares to be sold were acquired on 11/21/2025 via a stock option exercise from the issuer, paid in cash on the same date. Over the prior three months, the same seller, Timothy Cabral, reported sales of 20,000 shares of common stock on 09/24/2025 for gross proceeds of $1,500,000 and 6,360 shares on 09/02/2025 for gross proceeds of $421,655.28.
Doximity, Inc. (DOCS) reported a routine insider equity transaction by its Chief Financial Officer on a Form 4. On 11/15/2025, 5,121 shares of Class A common stock were withheld at a price of $49.62 per share to cover tax withholding obligations tied to the vesting of previously granted restricted stock units. After this tax-related withholding, the officer beneficially owns 364,672 shares of Class A common stock directly. The filing specifies that the share withholding followed an issuer election made in advance and does not represent a discretionary trade or open-market sale by the reporting person.
Doximity, Inc. reported an insider tax-withholding transaction by its Chief Executive Officer. On 11/15/2025, the CEO, who is also a director and 10% owner, had 8,005 shares of Class A Common Stock withheld by Doximity at a price of $49.62 per share. This withholding was done to cover tax obligations arising from the vesting of previously granted restricted stock units and was executed under a standing election by the company, rather than as a discretionary open-market trade by the executive. Following this transaction, the reporting person beneficially owned 2,241,053 shares of Doximity Class A Common Stock in direct ownership.
Doximity, Inc. (DOCS) director reported receiving 31,064 restricted stock units (RSUs) on November 15, 2025 under the company’s 2021 Stock Option and Incentive Plan. The RSUs vest in 10 equal quarterly installments after that date, contingent on the director’s continued service with the company at each vesting date. Each RSU converts into one share of Doximity Class A common stock at settlement, awarded at a stated price of $0 per share. Following this grant, the director beneficially owns 50,903 shares of Doximity Class A common stock in total.
Doximity, Inc. (DOCS) reported insider activity by its Chief Financial Officer. On 11/04/2025, the officer acquired 20,200 and 2,668 shares of Class A common stock, each labeled as a code C conversion from Class B following option exercises. The option exercises were at $4.12 and $2.21 per share, respectively.
Following these transactions, the officer beneficially owned 369,793 shares of Class A common stock, held directly. Footnotes state Class B shares are convertible into Class A on a one-for-one basis at the holder’s option, with automatic conversion upon certain events. The reported stock options carry expirations on 12/21/2030 and 09/28/2030, with vesting schedules as disclosed.
Doximity, Inc. reported strong quarterly performance. Revenue for the quarter ended September 30, 2025 reached $168.5 million, up from $136.8 million a year ago. Net income was $62.1 million versus $44.2 million, and diluted EPS was $0.31 compared to $0.22. Gross profit rose to $152.1 million while operating income increased to $63.7 million.
Operating cash flow for the six months was $156.0 million. The company ended the quarter with $169.2 million in cash and cash equivalents and $709.1 million in marketable securities. Doximity repurchased and retired 4,496,467 Class A shares for $220.2 million since program inception, with $279.8 million remaining authorized. The company completed the $36.3 million Pathway Medical acquisition, adding $18.7 million of developed technology and $17.0 million of goodwill.